Projects

International

LOGIC LAB – Molecular logic lab-on-a-vesicle for intracellular diagnostics
Molecular logic lab-on-a-vesicle for intracellular diagnostics
Program: Horizon 2020
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively.The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far.LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics.With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.
Duration: 1.11.2018 – 31.10.2022

National

Safe-MDs – In vitro hodnotenie bio-kompatibility zdravotníckych pomôcok (ZP) a inovatívnych bio-materiálov pre ZP
In vitro biocompatibility testing of medical devices (MDs) and new generation bio-materials for MDs
Program: SRDA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: Medical devices (MDs) have an irreplaceable role in the healthcare of the 21st century. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MD must not cause adverse effects and must demonstrate bio-compatibility with the tissues in the patient’s body.Most of the MDs\’ bio-compatibility assessments are still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress of validation of alternative methods, the MD regulations also utilize in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed human epidermis (RhE) test for intra-cutaneous testing into the ISO standard 10993-23.The presented research proposal focuses on the development of in vitro methods for biocompatibility assessment of medical devices (MDs) and innovative materials to be used as MDs polymers and that are intended for the use in the oral and vaginal cavities or on/in ocular epithelium.
Duration: 1.7.2020 – 30.6.2024
Prenatálne programovanie chorôb v dospelosti: možnosti terapie a prevencie následkov prenatálnej hypoxie u potomstva potkanov
Prenatal programming of adult diseases: treatment and prevention of outcomes of gestational hypoxia in rat offspring
Program: VEGA
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: Hypoxia during pregnancy, labor or early life stage is a major determinant of neurological morbidity and mortality in the neonatal period. In the last decade the fetal origin of chronic adult diseases was proposed as the most important factor in genesis of diabetes and hypertension in adulthood. The scientists showed that malnutrition, and inadequate oxygen supply during embryofetal development may lead to the inadequate apoptosis/necrosis, and caused maldevelopment of the organs responsible for regulation blood pressure, glucose, or improper brain wiring. Although the understanding of perinatal asphyxia-related pathophysiology is gradually increasing, limited therapeutic options are available to prevent or even mitigate the devastating process that unfolds after injury. Mitochondria-targeted antioxidants (MTA) are one of the most important therapies for providing neuroprotection in cerebral ischemia. The aim of the project will be to explore the possibilities of using MTA in late gestational hypoxia model.
Duration: 1.1.2020 – 31.12.2023
Hodnotenie biologickej kompatibility zdravotníckych pomôcok (ZP) a innovativnych materiálov pre výrobu ZP s využitím in vitro metód založených na 3D rekonštruovaných modeloch ľudského tkaniva.
Bio-compatibility assessment of medical devices and novel medical device materials using in vitro methods based on 3D reconstructed human tissue models.
Program: VEGA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Duration: 1.1.2020 – 31.12.2023
Vývoj produktov modifikáciou prírodných látok a štúdium ich multimodálnych účinkov na ochorenie COVID-19
Development of products by modification of natural compounds and study of their multi-modal effects onCOVID-19 disease
Program:
Project leader: RNDr. Májeková Magdaléna, PhD.
Duration: 1.7.2021 – 30.6.2023
Štúdium anatomicko-funkčných rozdielov v účinkoch aripiprazolu a kvetiapínu, atypických antipsychotík s podobnými terapeutickými vlastnosťami, ale rozdielnym vplyvom na dopaminergické receptory v mozgu, u experimentálnych zvierat
Investigation of anatomical-functional differences between the effects of aripiprazole and quetiapine, atypical antipsychotics with similar therapeutic indications, but different impact on brain dopaminergic receptors, in experimental animals
Program: SRDA
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: Antipsychotics (APs) represent a group of drugs used in the treatment of spectrum of psychotic and depressive disorders. However, frequency of ATs treatment is rather increasing than decreasing and growing number of atypical AP drugs have also been emerged over the last few years. In addition, APs treatment is connected with a number of unwanted side effects, such as extrapyramidal syndrome, akathisia, body mass increase, agranulocytosis, tardive dyskinesia, somnolencia, etc. Anatomical-functional investigations are incessantly bringing information about the effects of APs on the activity of neurons and their spatial distribution in the brain, which allows more precisely to define and predict the consequences of the APs treatment. The aim of the present study is to reveal the effect of acute and repeated treatment of two, relatively new atypical APs, aripiprazole (ARI) and quetiapine (QUE), on the activity of neurons in the forebrain and extra forebrain areas of the brain, to identify the phenotype (chemical) character of the targeted neurons, to investigate their impact on the behavior and to compare their impact on the activity of signaling pathways, expression of signaling molecules, and secretion of selected neuropeptides in anatomically precisely defined brain structures. The data of the present project will be new and will serve for the deeper understanding of the biology of serious mental disorders. They also may bring new impulses to the drug developing processing to prepare drugs with more directed and beneficial therapeutic features.
Duration: 1.7.2016 – 30.6.2020
Prenatálne programovanie chorôb v dospelosti: subchronická prenatálna asfyxia u potkanov ako vhodný model na štúdium mechanizmov embryo-fetálneho programovania neurobehaviorálnych zmien v dospelosti
Prenatal programming of psychiatric diseases: experimental approaches for evaluation of causes and mechanisms of their origin
Program: VEGA
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: There are many evidences on neurodevelopmental origin of mental diseases. Various environmental and maternal factors acting during prenatal period and early childhood can increase sensitivity of the individual to anxiety, depression or other mental disorders in later postnatal life. Insufficient oxygen and nutrition supply of tissues, excessive stress or chemical substances and drugs can adversely affect the development of the brain. The mechanisms and causes of prenatal programming will be studied using animal model of chronic prenatal asphyxia in rats to uncover basis for the increased sensitivity of the organism to the emergence and development of neurobehavioral and cardiovascular disorders in adulthood. Early detection of these mechanisms on the basis of molecular, biochemical and behavioral indicators can contribute to therapeutic interventions in the early stages of development and thus reduce or eliminate the occurrence of these diseases in later life.
Duration: 1.1.2016 – 31.12.2019
Mechanizmy, skorá detekcia a terapia asfyktického poškodenia v perinatálnom období – porovnanie experimentálnych údajov s klinickým obrazom asfyktického novorodenca
Mechanisms, early detection and therapy of asphyxial injury in perinatal period – comparison of experimental data with clinical observation of asphyxial newborns
Program: VEGA
Project leader: Doc. RNDr. Ujházy Eduard, CSc.
Annotation: The results from our studies concerning uncovering the mechanisms and possibilities of early detection of embryo-fetal damage confirmed that our proposed model of subchronic perinatal asphyxia using rat model is suitable for next studies. We will use this model for further expansion of knowledge about the mechanisms of actions of asphyxia in the process of late organogenesis and perinatal period. It is important to detect suitable biochemical and morphological markers to reduce the risk of complications due to asphyxia during development, as well as the possibility of its early therapy via antioxidant active ingredients of natural and synthetic origin. The ability of these compounds to bind to transport blood components (albumin, hemoglobin) will be monitored and a method for testing the effects on neuronal cell cultures will be developed. Integral part of this project will be correlations of given data from experimental studies with clinical observations in full-term asphyxiated newborns.
Duration: 1.1.2015 – 31.12.2018
Štúdium dôsledkov materskej depresie a podávania antidepresíva venlafaxínu na funkčný vývin mozgu a správanie potomstva potkanov
Study of consequences of maternal depression and antidepressant venlafaxine treatment on functional development of the brain and behavior of rat offspring
Program: VEGA
Project leader: RNDr. Dubovický Michal, CSc.
Duration: 1.1.2015 – 31.12.2018
Prenatálne programovanie psychiatrických porúch: experimentálne možnosti hodnotenia mechanizmov vzniku psychiatrických porúch na animálnych modeloch
Prenatal programming of psychiatric diseases: experimental approaches for evaluation of causes and mechanisms of their origin
Program: VEGA
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: Incidence of mental diseases in the developed countries has an increasing trend. At least one mental disease occurred per year approximately in 27% of EU inhabitants (more than 82 mil. people). It is estimated that till 2020, depression will be the main cause of morbidity in the developed countries. There are many evidences on neurodevelopmental origin of mental diseases. Various environmental and maternal factors acting during prenatal period and early childhood can increase sensitivity of the individual to anxiety, depression or other mental disorders in later postnatal life. Insufficient oxygen and nutrition supply of tissues, excessive stress or chemical substances and drugs can adversely affect the development of the brain. Objective of the project proposal will be the evaluation of key epigenetic factors which may play an important role in development of mental diseases.Up-to-date molecular biology as well as non-invasive methods of ethological analyses of appropriate animal models will be utilized.
Duration: 1.1.2012 – 31.12.2015
Štúdium mechanizmov a možností skorej detekcie embryofetálneho poškodenia v dôsledku intrautreinnej a perinatálnej hypoxie
The study of mechanisms and possible early detection of embryofetal damage caused by intrauterine perinatal hypoxia
Program: VEGA
Project leader: Doc. RNDr. Ujházy Eduard, CSc.
Annotation: Unfavorable conditions for intrauterine development represent foundation for health disturbances and morbidity after birth and in later life. For the proper diagnosis and reduction of hypoxia/ischemia (H/I) consequences it is essential to identify basic mechanisms and markers of H/I. Experimental approaches are important for the basic research. Chronic intrauterine hypoxia and acute perinatal hypoxia in rats belong to animal models appropriate for study H/I during sensitive stages of development. The aim of the project will be the sceening and evaluation of the indicators of H/I damage in mothers and fetuses during perinatal period. We will focus on observation of the structural and functional changes after H/I insult and finding suitable biomarkers of H/I in blood and urine samples. Integral part of this project will be correlations of given data from experimental studies with clinical observations in full-term asphyxiated newborns.
Duration: 1.1.2011 – 31.10.2014
Hodnotenie anxiolytických a antidepresívnych vlastností pyridoindolových derivátov
Early screening of anxiolytic and antidepressive properties of pyridoindole derivatives
Program: VEGA
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: Generalized anxiety disorder (GAD) is the most common of the anxiety disorders. More than 27% of adult Europeans are estimated to experience at least one form of mental illness during any one year.Introduced over 40 years ago, benzodiazepines (BZs) quickly became the most widely used psychotropic drugs. However, in recent years, attitudes toward these compounds have greatly changed, and growing awareness and concern about dependence liability, withdrawal phenomena, and short and long-term side effects have broughtthe long-term use of these compounds into question.In our project we would like to focus on pyridoindol derivatives, synthesized in our institute and study their potential anxiolytic or antidepressive effects in rats using behavioral and molecular approaches. Preliminary dataindicated their anxiolytic potential. These derivatives are chemically unrelated to benzodiazepines with remarkable antioxidant properties and they might be useful in therapy of anxiety disorders and depression.
Duration: 1.1.2009 – 31.12.2011
Využitie experimentálnych modelov perinatálnej asfyxie pri hodnotení porúch správania a možnosti ich farmakologického ovplyvnenia
Experimental models of perinatal asphyxia in evaluation of behavioral disorders and possibility of pharmacological intervention
Program: VEGA
Project leader: Doc. RNDr. Ujházy Eduard, CSc.
Annotation: Mental diseases are becoming the dread of the third millennium. Their incidence constantly increases and thus they become a serious medical and socio-economic issue. Depression and anxiety disorder are more frequent and affect people of all ages. The marked increase of the attention deficit-hyperactivity disorder is also alarming.Causes of these diseases have a multifactor character. Besides genetic predisposition, various negative factors acting during sensitive brain development play an important role. In our project we will focus on study of hypoxic/ischemic brain damage caused by perinatal asphyxia (PA) and its late neurobehavioural consequences using relevant animal models. Emphasis will be on evaluation of cognitive and motor functions and emotional/anxious responses in adulthood and senescence. Moreover, selected drugs with antioxidant and antiradical properties will be investigated for their potential preventive effects against consequenses of PAincluding in vitro safety screening.
Duration: 1.1.2008 – 31.12.2010
Vývinový pôvod metabolického syndrómu: hypertenzia, diabetes, dislipidémia
Developmental Origin of Metabolic Syndrome:Hypertension, Diabetes and Dyslipidemia
Program: VEGA
Project leader: MVDr. Bezek Štefan, DrSc.
Annotation: Project is dealing with the ehiopathogenesis of the metabolic syndrome. It is expected that repeated administration of novel pyridoindole derivative in rats will simultaneously influence multiple risk factors of experimental metabolic syndrome and reduce hypertension, hyperglycemia, hypercholesterolemia. The effect ofpyridoindole derivatives will be examined on apoptotic dysfunction of pancreatic ß-cells. The most efficient compound from the group will be identified with the prospect of its effective interference with the remission period in the early stages of juvenile diabetes. Investigation of mechanisms regulating fetal growth and development onthe model of hypoxia-reoxygenation and under diabetic condition of postimplantation whole embryo culture and influence of novel pyridoindole derivatives may be beneficial for designing new therapeutic strategies to prevent and treat intrauterine growth retardation.
Duration: 1.1.2008 – 31.12.2010
POLOS – Molekulové mechanizmy pôsobenia nových liečiv ovplyvňujúcich oxidačný stres – významný etiopatogenetický faktor početných chorôb
Molecular mechanisms of new drugs influencing oxidative stress – important ethiopathogenetic factor of numerous diseases
Program: SRDA
Project leader: Prof. MUDr. Bauer Viktor, DrSc.
Annotation: The project is aimed at understanding the mechanism of action of compounds with antioxidative and antiradical properties in tissue inflammation, ischemia/reperfusion, trauma, and chronic hyperglycemia, studied at preclinical level. It is supposed that the drugs may be used in inhibition of tissue oxidative impairment in stroke, neurotrauma, late consequences of diabetes, rheumatoid arthritis, myocardial infarction, etc. The outcome of the targeted analysis will be the suggestion of strategies in therapy, only rarely used in contemporary medicine. New knowledge on pharmacology of compounds interfering with oxidative stress (OS) will contribute to their use in combined prevention and therapy („the multibulletted concept“) of diseases in which OS is participating. The project will contribute to broadening the array of suitable medicines by new drugs with satisfactorily understood mechanism of action and will provide the rationale of pharmacologic intervention based on reduction of OS in tissues.
Duration: 1.9.2006 – 31.10.2009
Príspevok k prevencii a liečbe porúch správania vyvolaných hypoxicko-ischemickým poškodením mozgu v perinatálnom období: experimentálny model asfyxie a použitie látok s protiradikálovým a antioxidačným pôsobení
Contribution to prevention and treatment of behavioural disorders evoked by hypotic-ischaemic damage of the brain in perinatal period: experimental model of asphyxia and administration of substances with antiradical and antioxidative effects
Program: VEGA
Project leader: Doc. RNDr. Ujházy Eduard, CSc.
Duration: 1.1.2005 – 1.12.2007